BEIJING--(BUSINESS WIRE)--Pharmaron, a fully integrated contract research organization (CRO) offering laboratory and manufacturing services for pharmaceutical and biotech research and development, ...

BEIJING, October 28, 2025--(BUSINESS WIRE)--Pharmaron Beijing Co., Limited (Stock Code: 300759.SZ/3759.HK) (hereinafter referred to as "Pharmaron" and the "Company") today announced that it has ...

Pharmaron, a premier R&D service provider for the pharmaceutical and biotech industries, today announced a drug discovery partnership with AstraZeneca to support their global Innovative Medicines ...

HONG KONG & BEIJING--(BUSINESS WIRE)--Pharmaron Beijing Co., Ltd. (Stock Code: 300759.SZ/3759.HK) announced today that 117 million H-shares are listed on the Main Board of The Stock Exchange of Hong ...

BEIJING--(BUSINESS WIRE)--Pharmaron announced today that the company has received a Certificate of GLP Compliance, covering genetic toxicology and reproductive toxicology (DART Segments I and II), ...

Partnership to validate and promote the application of CN Bio’s PhysioMimix technology, with future opportunities for novel application and assay development CAMBRIDGE, England, April 23, ...

Pharmaron Beijing Co Ltd (300759) Assess today's live Pharmaron Beijing Co Ltd (300759) share price, performance and insights using our live Shenzhen: 300759 stock exchange data. Analyse the ...

BEIJING--(BUSINESS WIRE)--Pharmaron, a fully integrated CRO, today announced that the company reached a definitive agreement with a consortium led by CITIC M&A Fund and Legend Capital for an ...

Roughly half a year after closing its $63 billion megamerger with Allergan, AbbVie is letting go of the drugmaker's Liverpool, England biologics plant. AbbVie agreed to sell off the biomanufacturing ...

Chinese contract drugmaker Pharmaron Beijing Co. raised HK$4.6 billion ($589 million) after pricing its Hong Kong listing at the top end of a marketed range, people familiar with the matter said. The ...

Pharmaron, a US-based contract research organisation (CRO) with operations both at home and in China, has consolidated its presence in the latter market by acquiring preclinical specialist Bridge ...

Pharmaron Beijing, a China-based pharmaceutical research services company led by billionaire Lou Boliang, expects profit earned in the year to Dec. 31 to have climbed by as much as 45% to 1.7 billion ...